Fibroscan is a medical device for non-invasive quantification of liver fibrosis based on the technique of pulse elastography. Despite its validation in the evaluation of the severity of fibrosis in several chronic hepatopathies, its threshold value in the "healthy" subject has not been evaluated in Tunisia until now. We conducted a cross-sectional study including apparently healthy volunteers from Sfax between August 1, 2018 and February 28, 2020. Our patients were divided into 45 males and 46 females with a sex ratio of 0.97 and a mean age of 35.4±13.2y (18-62). The mean fibroscan value was 4.4±1.1Kpa (2.6-7.9). Thus, the normal fibroscan value ranged from 3.1Kpa (5th percentile) to 6.9 Kpa (95th percentile). The mean IQR was 0.6±0.4 (0.1-3.5) and the mean IQR/med was 12.7%±5.4 (2-29). There was no correlation between fibroscan value and BMI (p=0.46) or between fibroscan value and age (p=0.24). Gender did not influence the fibroscan value either.